Table 2 Comorbidity counts in trial participants and in the community, ordered according to the mean comorbidity counts in the community
Indication | Mean comorbidity count | % with comorbidity count > 2 | |||
|---|---|---|---|---|---|
Community (standardised to trials) | Trials | Ratio between mean counts (community:trials) | Community | Trials | |
Pulmonary fibrosis | 3.61 (3.49–3.75) | 2.17 (1.03–3.92) | 1.87 (0.90–3.49) | 0.88 (0.86–0.91) | 0.61 (0.28–0.90) |
Dementia | 3.44 (3.38–3.49) | 1.56 (1.10–2.18) | 2.27 (1.58–3.11) | 0.82 (0.81–0.83) | 0.46 (0.30–0.64) |
Pulmonary hypertension | 3.27 (3.01–3.53) | 2.09 (1.93–2.26) | 1.57 (1.39–1.75) | 0.80 (0.75–0.84) | 0.58 (0.53–0.63) |
Osteoporosis | 3.01 (2.99–3.03) | 2.07 (1.43–2.95) | 1.50 (1.02–2.10) | 0.79 (0.79–0.80) | 0.60 (0.42–0.79) |
Parkinson’s disease | 3.00 (2.90–3.10) | 1.36 (0.78–2.18) | 2.37 (1.37–3.86) | 0.75 (0.73–0.77) | 0.39 (0.18–0.64) |
Type 2 diabetes mellitus | 2.95 (2.94–2.96) | 0.79 (0.43–1.32) | 4.06 (2.23–6.83) | 0.78 (0.78–0.78) | 0.27 (0.19–0.36) |
Restless legs syndrome | 2.85 (2.81–2.89) | 1.68 (0.83–2.98) | 1.89 (0.96–3.42) | 0.74 (0.73–0.75) | 0.48 (0.20–0.80) |
Pulmonary disease, chronic obstructive | 2.76 (2.75–2.78) | 1.46 (1.00–2.07) | 1.96 (1.33–2.78) | 0.75 (0.74–0.75) | 0.43 (0.26–0.61) |
Thromboembolism | 2.52 (2.48–2.56) | 1.33 (0.80–2.00) | 2.00 (1.24–3.13) | 0.68 (0.67–0.70) | 0.38 (0.19–0.59) |
Systemic lupus erythematosus | 2.51 (2.35–2.68) | 2.30 (1.08–4.12) | 1.22 (0.60–2.32) | 0.69 (0.65–0.73) | 0.63 (0.29–0.92) |
Erectile dysfunction | 2.44 (2.43–2.45) | 1.08 (0.99–1.17) | 2.27 (2.08–2.47) | 0.69 (0.69–0.69) | 0.32 (0.29–0.36) |
Benign prostatic hyperplasia | 2.37 (2.34–2.40) | 1.11 (0.70–1.69) | 2.24 (1.40–3.36) | 0.66 (0.66–0.67) | 0.30 (0.16–0.50) |
Migraine | 2.33 (2.31–2.35) | 0.98 (0.63–1.42) | 2.50 (1.65–3.73) | 0.70 (0.69–0.71) | 0.26 (0.13–0.42) |
Atrial fibrillation | 2.22 (2.20–2.23) | 1.08 (1.07–1.10) | 2.05 (2.01–2.08) | 0.63 (0.63–0.64) | 0.29 (0.29–0.30) |
Osteoarthritis | 2.14 (2.13–2.15) | 1.79 (1.72–1.86) | 1.20 (1.15–1.24) | 0.61 (0.61–0.61) | 0.54 (0.51–0.56) |
Rheumatoid arthritis | 2.07 (2.03–2.10) | 1.14 (0.87–1.51) | 1.84 (1.37–2.39) | 0.59 (0.58–0.60) | 0.32 (0.22–0.44) |
Hypertension | 1.91 (1.90–1.91) | 0.50 (0.36–0.69) | 3.88 (2.76–5.28) | 0.54 (0.54–0.54) | 0.09 (0.05–0.15) |
Psoriatic arthropathy | 1.84 (1.78–1.89) | 0.67 (0.38–1.09) | 2.96 (1.71–4.88) | 0.51 (0.50–0.53) | 0.15 (0.06–0.30) |
Asthma | 1.81 (1.81–1.82) | 0.58 (0.35–0.92) | 3.32 (1.97–5.24) | 0.51 (0.50–0.51) | 0.12 (0.05–0.23) |
Inflammatory bowel disease | 1.55 (1.52–1.58) | 0.92 (0.68–1.18) | 1.73 (1.32–2.28) | 0.44 (0.43–0.45) | 0.23 (0.15–0.33) |
Axial spondyloarthritis | 1.42 (1.34–1.50) | 0.88 (0.43–1.58) | 1.79 (0.90–3.31) | 0.40 (0.37–0.43) | 0.22 (0.07–0.47) |
Psoriasis | 1.35 (1.34–1.37) | 0.69 (0.48–0.99) | 2.02 (1.36–2.80) | 0.39 (0.39–0.40) | 0.15 (0.08–0.26) |